109 related articles for article (PubMed ID: 8518222)
1. Carboplatin, methotrexate, vinblastine and epirubicin (Carbo-MVE) for transitional cell bladder carcinoma.
Solá C; Mallafré J; Mendoza Solórzano L; Segarra A; Daniels M; Viñolas N; Alcaraz A; Solé M; Alvarez R; Biete A
Ann Oncol; 1993 Apr; 4(4):313-6. PubMed ID: 8518222
[TBL] [Abstract][Full Text] [Related]
2. Chemotherapy with methotrexate, vinblastine, epirubicin and carboplatin (Carbo-MVE) in transitional cell urothelial cancer. A Hellenic Co-Operative Oncology Group study.
Skarlos DV; Aravantinos G; Linardou E; Kostakopoulos CA; Kastriotis I; Christodoulou C; Picramenos D; Giannakakis T; Dimopoulos K; Fountzilas G
Eur Urol; 1997; 31(4):420-7. PubMed ID: 9187901
[TBL] [Abstract][Full Text] [Related]
3. Treatment of advanced urothelial carcinoma with M-VECA (methotrexate, vinblastine, epirubicin and carboplatin).
Lorusso V; Pagliarulo A; Selvaggi FP; Durini E; Riccardi F; Comella P; Fiorillo C; De Lena M
J Chemother; 1996 Apr; 8(2):154-8. PubMed ID: 8708748
[TBL] [Abstract][Full Text] [Related]
4. Carboplatin, methotrexate, and vinblastine in the treatment of patients with advanced urothelial cancer. A phase II trial.
Boccardo F; Pace M; Guarneri D; Canobbio L; Curotto A; Martorana G
Cancer; 1994 Apr; 73(7):1932-6. PubMed ID: 8137220
[TBL] [Abstract][Full Text] [Related]
5. Methotrexate-paclitaxel-epirubicin-carboplatin (M-TEC) combination chemotherapy in patients with advanced bladder cancer: an open label phase II study.
Tsavaris N; Kosmas C; Skopelitis H; Dimitrakopoulos A; Kopterides P; Bougas D; Stravodimos K; Mitropoulos D; Alamanis C; Giannopoulos A
J Chemother; 2005 Aug; 17(4):441-8. PubMed ID: 16167525
[TBL] [Abstract][Full Text] [Related]
6. Adjuvant and neoadjuvant chemotherapy for invasive bladder cancer.
Kuroda M; Meguro N; Maeda O; Saiki S; Kinouchi T; Usami M; Kotake T
Cancer Chemother Pharmacol; 1994; 35 Suppl():S9-13. PubMed ID: 7527736
[TBL] [Abstract][Full Text] [Related]
7. A carboplatin-based regimen for the treatment of patients with advanced transitional cell carcinoma of the urothelium.
Small EJ; Fippin LJ; Ernest ML; Carroll PR
Cancer; 1996 Oct; 78(8):1775-80. PubMed ID: 8859191
[TBL] [Abstract][Full Text] [Related]
8. M-VEC (methotrexate, vinblastine, epirubicin, and cisplatin) with granulocyte colony-stimulating factor for the treatment of urothelial cancer: an effective and safe chemotherapy regimen.
Igawa M; Kadena H; Ueda M; Usui T
Cancer Chemother Pharmacol; 1994; 35 Suppl():S1-4. PubMed ID: 7527732
[TBL] [Abstract][Full Text] [Related]
9. Carboplatin, methotrexate, and vinblastine in outpatients with advanced transitional cell carcinoma of the bladder.
Pronzato P; Landucci M; Vaira F; Vigani A; Bertelli G
Am J Clin Oncol; 1995 Jun; 18(3):223-5. PubMed ID: 7747710
[TBL] [Abstract][Full Text] [Related]
10. Carboplatin-based versus cisplatin-based chemotherapy in the treatment of surgically incurable advanced bladder carcinoma.
Bellmunt J; Ribas A; Eres N; Albanell J; Almanza C; Bermejo B; Solé LA; Baselga J
Cancer; 1997 Nov; 80(10):1966-72. PubMed ID: 9366300
[TBL] [Abstract][Full Text] [Related]
11. Combination chemotherapy of cisplatin, methotrexate, vinblastine, and high-dose tamoxifen for transitional cell carcinoma.
Hsu CH; Chen J; Wu CY; Cheng AL; Pu YS
Anticancer Res; 2001; 21(1B):711-5. PubMed ID: 11299831
[TBL] [Abstract][Full Text] [Related]
12. Chemotherapy of advanced transitional-cell carcinoma of the bladder.
Miller RS; Torti FM
Cancer Chemother Pharmacol; 1992; 30 Suppl():S99-110. PubMed ID: 1394829
[TBL] [Abstract][Full Text] [Related]
13. M-VECA (methotrexate, vinblastine, epidoxorubicin and carboplatin) in the treatment of advanced urothelial carcinoma.
Lorusso V; Berardi F; Brandi M; Mastria A; Paradiso A; Catino AM; Tatulli C; De Lena M
Tumori; 1993 Jun; 79(3):191-4. PubMed ID: 8236502
[TBL] [Abstract][Full Text] [Related]
14. A pharmacologically guided phase I study of carboplatin in combination with methotrexate and vinblastine in advanced urothelial cancer.
Chatelut E; Chevreau C; Brunner V; Martinez M; Houin G; Bugat R; Canal P
Cancer Chemother Pharmacol; 1995; 35(5):391-6. PubMed ID: 7850920
[TBL] [Abstract][Full Text] [Related]
15. [Polychemotherapy using the M-VEC protocol (methotrexate, vinblastine, epirubicin, cisplatin) in advanced urinary bladder cancer--effectiveness and toxicity].
Rassweiler J; Rüther U; Bäuerle K; Bub P; Jipp P; Eisenberger F
Urologe A; 1989 Jan; 28(1):25-30. PubMed ID: 2922897
[TBL] [Abstract][Full Text] [Related]
16. Carboplatin, methotrexate, vinblastine, and epirubicin (M-VECa) as salvage treatment in patients with advanced bladder cancer: a phase II study.
Petrioli R; Roviello G; Fiaschi AI; Laera L; Miano ST; Bianco V; Francini E
Anticancer Drugs; 2015 Sep; 26(8):878-83. PubMed ID: 26053279
[TBL] [Abstract][Full Text] [Related]
17. Phase I trial of paclitaxel, carboplatin, and methotrexate with granulocyte colony-stimulating factor and leucovorin in advanced transitional cell carcinoma.
Edelman MJ; Meyers FJ; Houston J; Lauder I
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-68-S15-71. PubMed ID: 9346226
[TBL] [Abstract][Full Text] [Related]
18. First-line chemotherapy with cisplatin, methotrexate and vinblastine in metastatic bladder cancer.
Pajk B; Cufer T; Cervek J; Zakotnik B
Tumori; 1996; 82(5):453-5. PubMed ID: 9063522
[TBL] [Abstract][Full Text] [Related]
19. Chemotherapy with cisplatin, epirubicin and docetaxel in transitional cell urothelial cancer. Phase II trial.
Pectasides D; Visvikis A; Aspropotamitis A; Halikia A; Karvounis N; Dimitriadis M; Athanassiou A
Eur J Cancer; 2000 Jan; 36(1):74-9. PubMed ID: 10741298
[TBL] [Abstract][Full Text] [Related]
20. CMV front-line chemotherapy in transitional bladder carcinoma.
Paz-Ares L; Lianes P; Díaz-Puente M; Rivera F; Passas J; Costas P; Mendiola C; Cortés-Funes H
Ann Oncol; 1993 Feb; 4(2):147-50. PubMed ID: 8448083
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
